Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — FY2020 Q3 Earnings Presentation

55 slides from Daiichi Sankyo's earnings presentation, Jan 29, 2021

  1. Slide 1: FY2020 Q3 Financial Results Presentation

    FY2020 Q3 Financial Results Presentation DAIICHI SANKYO CO., LTD. Toshiaki Sai Executive Vice President and CFO January 29, 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Agenda

    Agenda 1 FY2020 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix 2

  4. Slide 4: Overview of FY2020 Q3 Results

    Overview of FY2020 Q3 Results (Bn JPY) FY2019 Q3 YTD FY2020 Q3 YTD YoY Results Results -2.4% Revenue 757.0 738.8 -18.2 Cost of sales 256.3 256.4 0.1 SG&A expenses 208.2 229.3 21.0 R&D expenses 136.9 163.6 26.7 -42.5% Operating Profit 155.6 89.5 -66.1 Profit before tax 160.0 99.6 -60.4 Profit attribu

  5. Slide 5: Revenue

    Revenue Decreased by 18.2 Bn JPY (Decreased by 12.3 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2019 Results FY2019 Results 757.0 Japan Tarlige +9.9 Memary -23.3 Japan 39.6 Japan Inavir -9.3 (incl. (incl.Vaccines, Vaccines,OTC) OTC) Lixiana -5.8 Daiichi Sankyo, Inc. Daiic

  6. Slide 6: Operating Profit

    Operating Profit Decreased by 66.1 Bn JPY (Decreased by 40.4 Bn JPY excl. forex impact and special items) (Bn JPY) Revenue -18.2 FY2019 Results FY2019 Results 155.6 incl. forex impact of -5.9 Revenue Revenue 0.0 18.2 Cost of Sales -12.8 (Profit increased) • Decrease by revenue decrease • Improvement

  7. Slide 7: Special Items

    Special Items (Bn JPY) FY2019 Q3 YTD FY2020 Q3 YTD YoY Results Results Restructuring costs 1.3 in SC Impairment loss Cost of sales 3.8 - 13.7 (intangible assets)*1 Gain on sales of -18.8 subsidiary*2 Gain on sales of fixed SG&A expenses -10.6 - 10.6 assets*3 R&D expenses - - - Total -24.3 - 24.3 - :

  8. Slide 8: Profit Attributable to Owners of the Company

    Profit Attributable to Owners of the Company Decreased by 58.5 Bn JPY (Bn JPY) FY2019 Results FY2019 Results 134.3 Financial Income/ -5.7 (Profit increased) Expenses etc. • Recognition of financial income due to Operating Profit 66.1 decrease in contingent consideration -4.8 Operating Profit 0.0 of

  9. Slide 9: Revenue: Major Business Units (incl. Forex Impact)

    Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2019 Q3 YTD FY2020 Q3 YTD YoY Results Results Japan 422.3 386.4 -35.9 Daiichi Sankyo Healthcare 52.9 51.5 -1.4 Daiichi Sankyo, Inc. 23.8 35.4 +11.6 Enhertu 0.0 18.0 +18.0 Olmesartan 7.8 7.2 -0.6 Welchol 8.6 3.9 -4.7 American Regent, Inc.

  10. Slide 10: Revenue: Major Products in Japan

    Revenue: Major Products in Japan (Bn JPY) FY2019 Q3 YTD FY2020 Q3 YTD YoY Results Results Nexium ulcer treatment 62.3 60.8 -1.5 Lixiana anticoagulant 65.6 59.8 -5.8 treatment for osteoporosis/ inhibitor of the progression of Pralia bone erosion associated with rheumatoid arthritis 24.3 26.4 +2.1 Mem

  11. Slide 11: Business Update

    1 FY2020 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix 10

  12. Slide 12: ENHERTU: Initiatives to Maximize Value

    ENHERTU® : Initiatives to Maximize Value ◆ Product sales FY2020 Q3 YTD Results: 20.7 Bn JPY <US 18.0 Bn JPY, JP 2.7 Bn JPY> ◆ Steady expansion in market and indication HER2+ Breast Cancer HER2+ Gastric Cancer Breast 3rd Line Gastric 3rd Line ➢ US ➢ JP Launched in January 2020*1 Indication expanded i

  13. Slide 13: ENHERTU: Revenue

    ENHERTU® : Revenue (Bn JPY) FY2020 FY2020 Forecast <Reference> Q3 YTD vs. Forecast Total Consideration (Received/ Receivable) Results (as of Oct.) Product Sales 20.7 34.9 - - Japan 2.7 5.6 - - US 18.0 29.2 - - 7.4 * 9.8* 1 1 Upfront payment - 149.0 *1 *1 Regulatory milestone payment 0.7 3.7 +1.2 34.

  14. Slide 14: Initiatives for Business Growth in Each Region

    Initiatives for Business Growth in Each Region ◆ Initiatives to strengthen the product portfolio and maximize product value are progressing steadily Prophylaxis of Treatment for Anti-epileptic migraine attacks large B-cell lymphoma agent EMGALITY® YESCARTA® VIMPAT® Japan Jan. 2021 Jan. 2021 Dec. 202

  15. Slide 15: Europe: New Products Launch

    Europe: New Products Launch ◆ Launched cholesterol-lowering treatment in-licensed from Esperion, NILEMDO® and NUSTENDI® in Germany in Nov. 2021 (Further launches planned in European markets) ◆ Bempedoic acid ◆ Fixed dose combination tablet of bempedoic acid ◆ First-in-class oral ACL* inhibitor and e

  16. Slide 16: R&D Update

    1 FY2020 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix 15

  17. Slide 17: ADC Update, Alpha Update, News Flow

    3 ADC Update Alpha Update News Flow IR material will use following terms ◆ DS-8201/trastuzumab deruxtecan =>ENHERTU®/T-DXd ◆ DS-1062/datopotamab deruxtecan =>Dato-DXd ◆ U3-1402/patritumab deruxtecan =>HER3-DXd 16

  18. Slide 18: ENHERTU: DESTINY-Lung01 Study Design

    ENHERTU®: DESTINY-Lung01 Study Design Phase 2 study of T-DXd, a novel antibody-drug conjugate, in patients with HER2-overexpressing or HER2-mutated metastatic NSCLC (NCT03505710) Cohort 1: Cohort 1a: Key eligibility criteria HER2-overexpressinga HER2-overexpressing • Unresectable/metastatic (IHC 3+

  19. Slide 19: DESTINY-Lung01 (HER2+): Patient Background

    DESTINY-Lung01 (HER2+): Patient Background Demographics and Baseline Patients (N = 49) Demographics and Baseline Patients (N = 49) Characteristics Characteristics Age, median (range), years 63.0 (37-85) Other gene abnormality status, n (%) <65 years, n (%) | ≥75 years, n (%) 27 (55.1%) | 2 (4.1%) EG

  20. Slide 20: DESTINY-Lung01 (HER2+): Efficacy

    DESTINY-Lung01 (HER2+): Efficacy Response Assessment by ICR IHC 3+ (n = 10) IHC 2+ (n = 39) Overall (N = 49) Confirmed ORR, 20.0% 25.6%% 24.5% n (95% CI) 2 (2.5-55.6) 10 (13.0-42.1) 12 (13.3-38.9) CR, n (%) 0 1 (2.6%) 1 (2.0%) PR, n (%) 2 (20.0%) 9 (23.1%) 11 (22.4%) SD, n (%) 6 (60.0%) 16 (41.0%) 2

  21. Slide 21: Best Percentage Change in Sum of Diameters From Baseline

    DESTINY-Lung01 (HER2+): Efficacy Best Percentage Change in Tumor Sizea With T-DXd 100 IHC 2+ (n = 35) IHC 3+ (n = 9) 80 Confirmed ORR: 24.5% (95% CI, 13.3%-38.9%) Best Percentage Change in Sum of 60 Diameters From Baseline 40 20 0 −20 −40 −60 −80 −100 aBest (minimum) percentage change from baseline

  22. Slide 22: Change in Tumor Size Over Time

    DESTINY-Lung01 (HER2+): Efficacy Change in Tumor Size Over Time 70 60 IHC 2+ (n = 35) IHC 3+ (n = 9) 50 40 % Change in Sum of Diameters 30 20 10 from Baseline 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 Baseline 6 12 18 24 30 36 42 48 56 60 Time (Weeks) from Enrollment Baseline is defined as the last

  23. Slide 23: DESTINY-Lung01 (HER2+): PFS and OS

    DESTINY-Lung01 (HER2+): Efficacy PFS and OS PFS (N = 49) OS (N = 49) Median: 5.4 months (95% CI, 2.8-7.0 months) Median: 11.3 months (95% CI, 7.8-NE) 1.0 1.0 0.8 0.8 PFS Probability OS Probability 0.6 0.6 0.4 0.4 0.2 Indicates upper and 0.2 Indicates upper and lower 95% CI lower 95% CI Censored case

  24. Slide 24: DESTINY-Lung01 (HER2+): Safety

    DESTINY-Lung01 (HER2+): Safety Type of Adverse Eventa Patients, n (%) N = 49 Type of Adverse Eventa Patients, n (%) N = 49 Any TEAE 49 (100.0%) TEAE grade ≥3 (>15%) Drug related 44 (89.8%) Decreased neutrophil count 10 (20.4%) TEAE grade ≥3 36 (73.5%) TEAE associated with dose discontinuationb Drug

  25. Slide 25: DESTINY-Lung01 (HER2+): Safety, ILD

    DESTINY-Lung01 (HER2+): Safety AEs of Special Interest: ILD All Patients (N = 49) n (%) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Any Grade/Total Adjudicated drug- 2 (4.1%) 3 (6.1%) 0 0 3 (6.1%) 8 (16.3%) related ILDa Adjudicated drug-related ILDsb Grade 5 ILDc events • Median time to onset was 64.5 d

  26. Slide 26: DESTINY-Lung01 (HER2+): Summary

    DESTINY-Lung01 (HER2+): Summary T-DXd Showed Preliminary Evidence of Antitumor Activity in Patients With HER2-Overexpressing NSCLC Efficacy Results • In extensively pretreated patients who had previously received a median of 3 lines of therapies (range, 1-8), T-DXd 6.4 mg/kg demonstrated • A confirm

  27. Slide 27: Dato-DXd: TROPION-PanTumor01 Study Design

    Dato-DXd: TROPION-PanTumor01 Study Design Phase 1 Dose Escalation and Expansion Study Key inclusion criteria Dose escalation1 Dose expansion • Relapsed/refractory advanced/metastatic NSCLC 50 patients at 4 mg/kgc • Unselected for TROP2 Dato-DXd 0.27 mg/kg Primary objectives expressiona to 10 mg/kg Q

  28. Slide 28: TROPION-PanTumor01: Patient Background

    TROPION-PanTumor01: Patient Background Dato-DXd dose 4 mg/kg 6 mg/kg 8 mg/kg Characteristic (n = 50) (n = 45) (n = 80) Male, n (%) 27 (54) 26 (58) 41 (51) Median age (range), y 61 (35-82) 62 (45-76) 64 (31-84) United States, n (%); Japan, n (%) 29 (58); 21 (42) 36 (80); 9 (20) 63 (79); 17 (21) ECOG

  29. Slide 29: TROPION-PanTumor01: Treatment Status

    TROPION-PanTumor01: Treatment Status • Median follow-up of 7.4 months (range, 0.10-21.7 months) – Follow-up was shorter for patients treated with 4 mg/kg and 6 mg/kg than with 8 mg/kg of Dato-DXd • Patients receiving 8 mg/kg discontinued treatment due to AEs more frequently and had a lower median re

  30. Slide 30: TROPION-PanTumor01: Safety

    TROPION-PanTumor01: Safety • Dato-DXd demonstrated a manageable safety profile – More grade ≥3 TEAEs and serious TEAEs were observed with 8 mg/kg than with 4 mg/kg and 6 mg/kg Dato-DXd dose 4 mg/kg 6 mg/kg 8 mg/kg (n = 50) (n = 45) (n = 80) n (%) n (%) n (%) TEAE 48 (96) 41 (91) 79 (99) Grade ≥3 11

  31. Slide 31: TROPION-PanTumor01: Safety, TEAEs

    TROPION-PanTumor01: Safety Treatment-Emergent Adverse Events TEAEs in ≥15% of Patientsa Nausea • TEAEs were predominantly nonhematologic Stomatitis Alopecia • Rates of grade ≥3 stomatitis and mucosal inflammation were higher with 8 mg/kg vs Fatigue 4 and 6 mg/kgc Vomiting Decreased appetite • 14 out

  32. Slide 32: TROPION-PanTumor01: Pharmacokinetics

    TROPION-PanTumor01: Pharmacokinetics • The PK profile of Dato-DXd remained consistent throughout 3 cycles of treatment, regardless of dose Dato-DXd dose Dato-DXd Total datopotamab (mAb) DXd (payload) 4 mg/kg 6 mg/kg 8 mg/kg Concentration, mg/mL 100 1 0.01 0.0001 0 7 14 21 0 7 14 21 0 7 14 21 Cycle 1

  33. Slide 33: TROPION-PanTumor01: Efficacy

    TROPION-PanTumor01: Efficacy Best Change in Sum of Diameters and Overall Response (BICR) Change in Sum of Diameters for Target Lesions (BICR) 80 6 mg/kg Best percent change in SoD from baseline, % Dato-DXd dose 100 60 4 mg/kg Best percent change in SoD, % 80 6 mg/kg 40 60 8 mg/kg 40 20 20 0 0 −20 −2

  34. Slide 34: TROPION-PanTumor01: Summary

    TROPION-PanTumor01: Summary • In the ongoing TROPION-PanTumor01 phase 1 study, datopotamab deruxtecan (Dato-DXd; DS-1062) demonstrated highly encouraging antitumor activity and a manageable safety profile in heavily pretreated NSCLC patients – 84% received prior immunotherapy, and 94% received prior

  35. Slide 35: HER3-DXd: Genomic Alterations Observed in NSCLC P1 Study

    HER3-DXd: Genomic Alterations Observed in NSCLC P1 Study Observed Mechanisms of EGFR TKI Resistance in Pretreatment Tumor Tissue and ctDNA (Percentages Shown for U31402-A-U102 Study Specimens) 8% 53% 8% 4% Other HER3 mut 2% HER4 mut 8% 12% 16% CDKN2A mut 6% 4% NTRK2 mut 2% 22% Schematic representati

  36. Slide 36: HER3-DXd: Efficacy in Various Genomic Alterations

    HER3-DXd: Efficacy in Various Genomic Alterations Antitumor Activity of HER3-DXd 5.6 mg/kg Q3W in EGFR-Mutated NSCLC With Diverse TKI Resistance Mechanisms N = 49a Median follow-up: 5 months 40 40 from baseline (BICR), % 30 30 20 20 Best change in SoD 10 10 00 -10−10 −20 -20−30 -30−40 -40−50 -50−60

  37. Slide 37: HER3-DXd: HER3 Expression in NSCLC Tumors

    HER3-DXd: HER3 Expression in NSCLC Tumors Baseline Membrane HER3 Expression and Association With Time Since Most Recent EGFR TKI Therapya,b 300 300 Baseline membrane 250 Baseline membrane HER3 H score HER3 H score 200 200 150 100 100 50 0 0 All patients Evaluable patients, n 43 Days between last EGF

  38. Slide 38: HER3-DXd: Association of HER3 Expression and Response

    HER3-DXd: Association of HER3 Expression and Response HER3 Membrane H Score and Association With Confirmed Clinical Response by BICR 300 Baseline membrane HER3 H score 200 100 0 cBOR (BICR) CR/PR SD PD NE Evaluable patients, n 9 19 6 8 Median membrane HER3 H 220 175 126.5 190 score (range) (140-268)

  39. Slide 39: ADC Update, Alpha Update, News Flow

    3 ADC Update Alpha Update News Flow 38

  40. Slide 40: DS-6000: Target CDH6

    DS-6000: Target CDH6 CDH6 (cadherin 6) ◆ Member of CDH family. The function of CDH6 is still to be fully elucidated. It is said to be related to cell-cell adhesion, epithelial to mesenchymal transition (EMT) and metastasis ◆ In developmental stage, CDH6 is expressed in kidney, endometrium, placenta

  41. Slide 41: DS-6000: Target Indication and Phase 1 Study Design

    DS-6000: Target Indication and Phase 1 Study Design Renal cell carcinoma ◆ Disease: Cancer of renal parenchymal cells, which accounts for about 90% of kidney cancers ◆ SOC: 1L; I/O + I/O or I/O + TKI, 2L~: cabozantinib, VEGFR TKI, and etc. ◆ Incidence: 166,000 (JP/US/EU5)* Ovarian Cancer ◆ Disease:

  42. Slide 42: DS-1647 (G47Δ): Malignant Glioma

    DS-1647 (G47Δ): Malignant Glioma ◆ Dec. 2020: Submitted in Japan Malignant glioma ◆ Disease: Glioma accounts for about 1/4 of brain tumors and is classified into 4 stages according to malignancy. Those with high malignancy (grades 3 and 4) are called malignant gliomas ◆ SOC: Radiation therapy + temo

  43. Slide 43: Efient: Ischemic Stroke

    Efient® : Ischemic Stroke ◆ Dec. 2020: sNDA submitted for ischemic stroke in Japan Ischemic Stroke (non-cardioembolic ischemic stroke) ◆ Disease: Non-cardioembolic ischemic stroke represented by atherothrombotic and lacunar stroke is caused mainly by thrombosis in the artery and has a high risk of r

  44. Slide 44: DS-5141: Duchenne Muscular Dystrophy

    DS-5141: Duchenne Muscular Dystrophy ◆ Dec. 2020: TLR obtained from phase 1/2 study(12 and 48-week study) Duchenne Muscular Dystrophy (amenable to Exon 45 skipping) ◆ Disease: Hereditary muscle disorder caused by abnormalities in the dystrophin gene resulting in the absence of dystrophin protein pro

  45. Slide 45: Tarlige: Central Neuropathic Pain

    Tarlige® : Central Neuropathic Pain ◆ Dec. 2020: TLR obtained from phase 3 study Central Neuropathic Pain ◆ Disease: Pain caused by central nervous system damage or associated dysfunction, accompanied by various sensory abnormalities (e.g. central post-stroke pain, central neuropathic pain after spi

  46. Slide 46: ADC Update, Alpha Update, News Flow

    3 ADC Update Alpha Update News Flow 45

  47. Slide 47: News Flow

    News Flow As of January 2021 Phase 3 DESTINY-Breast02: HER2 positive BC, 3L • TLR anticipated in FY2021 Q2 Phase 3 DESTINY-Breast03: HER2 positive BC, 2L • TLR anticipated in FY2021 Q2 ENHERTU® Phase 3 DESTINY-Breast04: HER2 low BC, post chemo • TLR anticipated in FY2021 Q2 Phase 2 DESTINY-Lung01: H

  48. Slide 48: Appendix

    1 FY2020 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix 47

  49. Slide 49: Major R&D Milestones in FY2020 (3 ADCs)

    Major R&D Milestones in FY2020 (3 ADCs) As of January 2021 FY2020 FY2021 Project Target Indications [phase, study name] Q1 Q2 Q3 Q4 H1 CHMP positive HER2+, 3L [P2 pivotal, DESTINY-Breast01] EU submitted EU approved opinion HER2+, 3L [P3, DESTINY-Breast02] TLR anticipated HER2+, 2L [P3, DESTINY-Breas

  50. Slide 50: Major R&D Milestones in FY2020 (Alpha)

    Major R&D Milestones in FY2020 (Alpha) As of January 2021 FY2020 FY2021 Project Target Indications [phase, study name, region] Q1 Q2 Q3 Q4 H1 CHMP negative Tenosynovial giant cell tumor [P3, ENLIVEN,EU] Pexidartinib opinion Tenosynovial giant cell tumor [P2, JP] Study start planned Approval G47Δ Mal

  51. Slide 51: Major R&D Pipeline: 3 ADCs

    Major R&D Pipeline: 3 ADCs As of January 2021 Phase 1 Phase 2 Phase 3 Submitted (JP/US) NSCLC, TNBC (US/EU/Asia) HER2+ BC 2L~/1L (US/EU/Asia) TNBC (durvalumab combo) (JP/US/EU/Asia)HER2+ BC 3L TROPION-PanTumor01 DESTINY-Breast07 BEGONIA DESTINY-Breast02 (JP/US) NSCLC (w/o actionable (US/EU/Asia) HER

  52. Slide 52: Major R&D Pipeline: Alpha

    Major R&D Pipeline: Alpha As of January 2021 Phase 1 Phase 2 Phase 3 Submitted DS-7300 (JP/US) DS-3201 (JP/US) DS-3201 (JP) Quizartinib (JP/US/EU/Asia) DS-1647 (G47Δ) (JP) B7-H3-directed ADC EZH1/2 inhibitor EZH1/2 inhibitor FLT3 inhibitor Oncolytic HSV-1 Solid tumors Non-Hodgkin‘s lymphomas ATL/L 1

  53. Slide 53: Efient: Ischemic Stroke sNDA

    Efient® : Ischemic Stroke ◆ Ischemic stroke patients: ◆ Ischemic stroke patients ◆ Atherothrombotic/lacunar N=3,747 (elderly/underweight): stroke patients: N=234 ◆ 19% risk reduction in N=654 ◆ Incidence of atherothrombotic/lacunar ◆ No cerebrocardiovascular cerebrocardiovascular event stroke patien

  54. Slide 54: Abbreviations

    Abbreviations Abbrevia English Implications tions AE Adverse event Undesirable experience associated with the use of a medical product in a patient BTD Breakthrough therapy designation Designation granted by US FDA that expedites drug development CR Complete response Complete response (complete reso

  55. Slide 55: Contact information regarding this material

    Contact information regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: [email protected]

Daiichi Sankyo Company — FY2020 Q3 Earnings Presentation on 6ix